Navigation Links
Survival Rate of Cancer Patients in Korea Ranked in the Top in the World
Date:2/6/2012

SEOUL, South Korea, Feb. 6, 2012 /PRNewswire-Asia/ -- As the whole world battles against cancer, the survival rate of cancer patients in Korea has shown a great improvement. Cancer is still the number one cause of death in Korea, but about half of Korean cancer patients have, in recent times, managed to survive for more than ten years, which illustrates that world class cancer treatments are available in Korea.

The Korean government recently announced that the survival rate of Korean cancer patients had improved from 59.5% in 2008 to 62.0% in 2009, while the cancer mortality rate showed a 19% decrease in 2006 and a 21% decrease in 2008. In addition, the 2011 Health Care Quality Indicators released by OECD member countries indicated that Korea excelled in the treatment of uterine cancer and that its survival rate for stomach cancer, 65.3%, well surpassed those of the USA (26%), Europe (24.9%), Japan (62.1%) and Canada (22%). In addition, the survival rate from thyroid cancer in Korea is 99.7% while that of breast cancer is 90.6%.

Similarly, Korean Ministry of Health & Welfare carried out an interim assessment of the '10-Year Plan to Conquer Cancer' and found out that the plan had exceeded its initial objective in 2011. Thus, the Ministry upgraded the survival rate target by 2015 from 54% to 67% following the deliberation by the National Cancer Management Committee. Cancer survival rate refers to the percentage of people able to survive five years after being diagnosed with and treated for cancer. It actually means the complete recovery rate.

Such excellent survival rates for Korean cancer patients have been due to the continuous efforts of the government to manage cancer and advance the medical technology. Korea has been building its reputation in robot-assisted surgery, a cutting edge cancer treatment technology, which has every year attracted many medical experts from Japan, Taiwan and many other countries to the National Cancer Center to learn the robot-assisted surgical techniques.

Proton therapy at the National Cancer Center is one of the most renowned cancer treatment techniques in Korea. Proton therapy is a type of particle therapy that uses hydrogen ions, which are 1800 times heavier than electrons. Protons accelerated by a cyclotron irradiate a human body containing cancerous tumors in order to destroy the DNA contained by these tumors.

For more information:
Please contact Yang Ji-young of the Korea Health Development Institute's Global Healthcare Business Department at+82-43-713-8248 or kknmk0612@gmail.com.


'/>"/>
SOURCE Korea Health Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Published in Neuro-Oncology Journal Shows Brain Tumor Eradication and Prolonged Survival in Mice Treated With Toca 511 and 5-FC
2. Phase III Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
3. Phase 3 Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
4. Clinical Trials Are Key to Doubling the Survival Rate for Pancreatic Cancer
5. Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
6. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
7. Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
8. The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer
9. Health of Recipients and Quality of Donor are Greater Factors in Survival than Metabolic Factors
10. bioTheranostics CancerTYPE ID® Linked With Improved Clinical Outcome and Longer Survival
11. Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
(Date:3/28/2017)... BOSTON , March 28, 2017  Market ... today announced a partnership with premium news content ... pharmaceutical companies to extract key insights from Dow ... mining technology. The Linguamatics I2E platform ... 20 global pharmaceutical companies. The Linguamatics-Dow Jones partnership ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul ... , WHAT: , Medical doctors and PhD scientists will speak to the press on ... Trump in support of an independent vaccine safety commission. , WHERE: , Zenger ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management Association (RBMA) ... as its new executive director. Mr. Still was selected through a careful months-long search ... as he is known to our members, has been a part of building the ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... MA (PRWEB) , ... March 28, 2017 , ... ... for direct measurement of corrosive ions found in power plant water and steam. ... components such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. ...
Breaking Medicine News(10 mins):